GLP-1 Agonist FDA Approvals: Complete History and Timeline
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
Explore the complete history and timeline of GLP-1 agonist FDA approvals. This in-depth article covers the evolution of these revolutionary drugs for diabetes and weight loss.
The Complete History and Timeline of GLP-1 Agonist FDA Approvals
The landscape of metabolic disease treatment has been revolutionized by the advent of glucagon-like peptide-1 (GLP-1) receptor agonists. These powerful medications have not only transformed the management of type 2 diabetes but have also emerged as a groundbreaking therapy for obesity and weight management. Understanding the GLP-1 agonist FDA approval history provides crucial insights into the evolution of these drugs, from their initial discovery to their current status as blockbuster therapeutics. This article provides a comprehensive timeline of GLP-1 agonist FDA approvals, details the key differences between the available agents, and explores the future of this rapidly advancing field.
What are GLP-1 Agonists?
GLP-1 receptor agonists are a class of medications that mimic the action of the natural hormone glucagon-like peptide-1. This hormone plays a crucial role in regulating blood sugar levels by stimulating insulin secretion and inhibiting glucagon release from the pancreas in a glucose-dependent manner. Additionally, GLP-1 agonists slow down gastric emptying, which is the process of food moving from the stomach to the small intestine. This action, combined with a direct effect on the brain's appetite centers, leads to increased feelings of fullness and reduced food intake, contributing to weight loss. PMID: 31189805 PMID: 35499942
The History and Timeline of GLP-1 Agonist FDA Approvals
The journey of GLP-1 agonists from discovery to their current prominence is a testament to decades of research and development. The following table provides a chronological overview of the key FDA approvals that have marked the evolution of this important class of drugs.
| Brand Name | Generic Name | Sponsor / Manufacturer | Indication | Launch Date |
|---|---|---|---|---|
| Byetta | exenatide | AstraZeneca | Diabetes | 4/28/05 |
| Victoza | liraglutide | Novo Nordisk | Diabetes | 1/25/10 |
| Bydureon | exenatide | AstraZeneca | Diabetes | 1/27/12 |
| Tanzeum | albiglutide | GSK | Diabetes | 4/15/16 |
| Trulicity | dulaglutide | Eli Lilly | Diabetes | 9/18/24 |
| Saxenda | liraglutide | Novo Nordisk | Weight Loss | 12/23/14 |
| Adlyxin | lixisenatide | Sanofi | Diabetes | 7/27/20 |
| Bydureon BCise | exenatide | AstraZeneca | Diabetes | 10/20/17 |
| Ozempic | semaglutide | Novo Nordisk | Diabetes | 12/15/17 |
| Rybelsus | semaglutide | Novo Nordisk | Diabetes (oral formulation) | 1/16/20 |
| Wegovy | semaglutide | Novo Nordisk | Weight Loss | 6/4/21 |
| Mounjaro | tirzepatide | Eli Lilly | Diabetes | 5/13/22 |
| Zepbound | tirzepatide | Eli Lilly | Weight Loss | 11/8/23 |
---
The specialists at TeleGenix can help you understand if GLP-1 therapy is right for you.
---
Key Milestones in GLP-1 Agonist Development
The approval of Byetta in 2005 marked the beginning of a new era in diabetes treatment. This first-in-class GLP-1 receptor agonist offered a novel mechanism of action for improving glycemic control. Subsequent approvals, such as Victoza in 2010, introduced new formulations with different dosing schedules. The development of long-acting injectable formulations like Bydureon and Trulicity further improved convenience for patients.
A significant turning point in the GLP-1 agonist FDA approval history was the approval of Saxenda in 2014 for chronic weight management. This was the first time a GLP-1 agonist was approved specifically for obesity, opening up a new therapeutic avenue for millions of patients struggling with this condition. The subsequent approvals of Wegovy and Zepbound for weight loss have further solidified the role of GLP-1 agonists in this area.
Another major innovation was the development of an oral formulation of semaglutide, Rybelsus, approved in 2020. This was a significant breakthrough, as it provided a non-injectable option for patients. The most recent additions to the GLP-1 family, Mounjaro and Zepbound, are dual-acting GIP and GLP-1 receptor agonists, which have demonstrated even greater efficacy in both glycemic control and weight loss. PMID: 35608219 PMID: 36259720
Internal Links
References
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any treatment.*
---